<div id="readability-page-1"><div><ul> <li>If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value today, the key is to look past the share price and focus on what the underlying valuation signals are telling you.</li> <li>The stock has been relatively flat over the past month with a 0.2% return, but the 48.9% return over the last year contrasts with a small 0.5% decline in the last 7 days and a modest 0.1% return year to date, which can change how investors see both its potential and its risks.</li> <li>Recent attention on the company has centered on its position in the pharmaceuticals and biotech space, where progress on therapies and regulatory updates often influence investor sentiment. For Amicus Therapeutics, news around its treatment portfolio and pipeline has helped frame expectations about future cash flows and what investors might be willing to pay for that story.</li> <li>Simply Wall St assigns Amicus Therapeutics a valuation score of 5 out of 6, suggesting that on this framework the stock screens as undervalued on most checks. Next, we walk through the different valuation approaches behind that score before finishing with a way to put all those methods into a single, clearer picture.</li> </ul> Amicus Therapeutics delivered 48.9% returns over the last year. See how this stacks up to the rest of the Biotechs industry. <h3>Approach 1: Amicus Therapeutics Discounted Cash Flow (DCF) Analysis</h3> A Discounted Cash Flow model takes estimates of the cash a company could generate in the future, then discounts those cash flows back into today’s dollars to arrive at an estimated intrinsic value per share. For Amicus Therapeutics, the latest twelve month Free Cash Flow is about $6.2 million. Using a 2 Stage Free Cash Flow to Equity model based on analyst inputs and extended projections from Simply Wall St, future Free Cash Flow is projected to reach about $697.5 million in 2030. Intermediate years sit between these points, with discounted values supplied for each year through 2035. When all those discounted cash flows are added together and divided by the number of shares, the model arrives at an estimated intrinsic value of about $60.28 per share. Compared with the recent share price around $14.28, the DCF output suggests the shares trade at a 76.3% discount to this estimate, which screens as materially undervalued on this method. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Amicus Therapeutics is undervalued by 76.3%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows. <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/dcf"/><figcaption>FOLD Discounted Cash Flow as at Jan 2026</figcaption></figure> Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amicus Therapeutics. <h3>Approach 2: Amicus Therapeutics Price vs Sales</h3> For a company like Amicus Therapeutics, where the investment story is closely tied to revenue traction in therapies rather than current accounting profits, the P/S ratio is a practical way to think about value. It links what you pay per share directly to the sales the business is generating. What counts as a reasonable P/S depends on how the market sees growth potential and risk. Higher expected growth and stronger business quality can justify a higher multiple, while higher uncertainty or weaker margins usually call for a lower one. Amicus currently trades on a P/S of 7.38x. That sits below the Biotechs industry average of 11.52x and the peer average of 12.94x, which on simple comparisons can make the stock look inexpensive. Simply Wall St goes a step further with its proprietary Fair Ratio of 8.47x. This Fair Ratio reflects what P/S might be expected after considering factors like earnings growth, profit margins, risk profile, industry and market cap, rather than relying only on broad peer groups. Comparing the current 7.38x P/S with the 8.47x Fair Ratio suggests the shares are trading below that Fair Ratio benchmark. Result: UNDERVALUED <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/ps-multiple-vs-industry"/><figcaption>NasdaqGM:FOLD P/S Ratio as at Jan 2026</figcaption></figure> P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1417 companies where insiders are betting big on explosive growth. <h3>Upgrade Your Decision Making: Choose your Amicus Therapeutics Narrative</h3> Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is your story about a company, where you connect your view of its products, competitive position and risks to specific numbers like future revenue, earnings, margins and the fair value you think is reasonable. On Simply Wall St, Narratives link that story to a full financial forecast, then compare the Fair Value that results from your assumptions with the current share price. This can help you decide whether Amicus Therapeutics appears attractive, fully priced or expensive based on your own expectations rather than a generic model. You can create and explore Narratives on the Community page of Simply Wall St, where millions of investors share their views and each Narrative automatically refreshes when new information such as earnings releases or company news is added to the platform. For example, one investor might build a Narrative for Amicus Therapeutics with very optimistic revenue growth and margin assumptions that point to a high Fair Value, while another might use much more conservative inputs that result in a far lower Fair Value. This gives you a clear sense of how different views translate into different price signals. Do you think there's more to the story for Amicus Therapeutics? Head over to our Community to see what others are saying! <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4892cc3b-51fb-459b-99c0-de7e1a5858bf/chart/quote-price"/><figcaption>NasdaqGM:FOLD 1-Year Stock Price Chart</figcaption></figure> This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</div></div>

FOLD

Amicus Therapeutics (FOLD) has seen a 48.9% gain over the past year, currently priced at around $14.28. Despite a recent flat performance, analysts suggest the stock is undervalued. A Discounted Cash Flow analysis indicates a potential intrinsic value of $60.28 per share, suggesting a 76.3% discount. Additionally, the Price-to-Sales ratio of 7.38x is below industry averages, reinforcing the undervaluation perspective. Investors are encouraged to consider the company's treatment portfolio and future cash flow projections when assessing its value.

Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain?